Skip to content
Homepage
Author:
Transgene S.A.
Posted Date:
June 24, 2026
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
Transgene S.A.
June 24, 2026
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
Transgene S.A.
June 21, 2026
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
Transgene S.A.
May 25, 2026
Transgene’s Combined General Meeting of May 22, 2026
Transgene S.A.
May 22, 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
Transgene S.A.
May 4, 2026
Transgene Provides Business and Financial Update for Q1 2026
Transgene S.A.
April 29, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene S.A.
April 12, 2026
Availability of Transgene’s 2025 Universal Registration Document (URD)
Transgene S.A.
April 9, 2026
Transgene to Participate in Upcoming Investor Meetings
Transgene S.A.
April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Transgene S.A.
April 2, 2026
1
2
Next
